Hajjar, Joud
Mendoza, Tito
Zhang, Liangliang http://orcid.org/0000-0001-5986-2260
Fu, Siqing http://orcid.org/0000-0002-1933-0419
Piha-Paul, Sarina A.
Hong, David S.
Janku, Filip http://orcid.org/0000-0002-8123-4065
Karp, Daniel D.
Ballhausen, Alexej
Gong, Jing
Zarifa, Abdulrazzak
Peterson, Christine B. http://orcid.org/0000-0003-3316-0468
Meric-Bernstam, Funda
Jenq, Robert
Naing, Aung http://orcid.org/0000-0002-4803-8513
Article History
Received: 15 November 2020
Accepted: 18 February 2021
First Online: 12 March 2021
Competing interests
: JH reports research support from Immune Deficiency Foundation, Jeffery Modell Foundation and Chao Physician-Scientist, and Baxalta and has served on an advisory board for Takeda, CSL, Behring, Horizon, and Pharming, outside the submitted work; SF reports clinical trial research support from AstraZeneca, Abbisko, Anaeropharma Science, Arrien Pharmaceuticals, BeiGene, BioAtla, LLC, Boehringer Ingelheim, Eli Lilly, Hookipia Biotech, Huya Bioscience International, IMV, Inc., Innovent Biologics, Co., Ltd., Lyvgen Biopharm, Co., Ltd., MacroGenics, Medivir AB, Millennium Pharmaceuticals, Inc., Nerviano Medical Sciences, NeuPharma, Inc., NIH/NCI, Novartis, OncoMed Pharmaceuticals, Parexel International, LLC, Sellas Life Sciences Group, Soricimed Biopharma, Inc., Tolero Pharmaceuticals, outside the submitted work, grants from NIH/NCI; SAP-P reports grants from AbbVie, Inc., ABM Therapeutics, Inc., Acepodia, Inc., Alkermes, Inc., Aminex Therapeutics, Amphivena Therapeutics, Inc., BioMarin Pharmaceutical, Inc. , Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharmaceutical Co., Daichi Sankyo, Inc., Eli Lilly, Five Prime Therapeutics, Genmab A/S, GlaxoSmithKline, Helix BioPharma Corp., Incyte Corp., Jacobio Pharmaceuticals Co., Ltd, Medimmune, LLC, Medivation, Inc., Merck Sharp and Dohme Corp., Novartis Pharmaceuticals, Pieris Pharmaceuticals, Inc., Pfizer, Principia Biopharma, Inc., Puma Biotechnology, Inc., Rapt Therapeutics, Inc., Seattle Genetics, Taiho Oncology, Tesaro, Inc., Transthera Bio, and NCI/NIH Core Grant, outside the submitted work; DSH reports research/grant funding from Abbvie, Adaptimmune, Amgen, Astra-Zeneca, BMS, Daiichi-Sankyo, Eisai, Fate Therapeutics, Genmab, Ignyta, Kite, Kyowa, Lilly, Medimmune, Merck, Merrimack, Mirati, MIRNA, Molecular Templates, Mologen, NCI-CTEP, Novartis, Pfizer; personal fees from Axiom, Baxter, GLG, Group H, Guidepoint Global, Jannsen, Medscape, Numab, Trieza Therapetics; research/grant funding and personal fees from Bayer, Genentech, Infinity, LOXO, Seattle Genetics, Takeda; and other from Molecular Match, OncoResponse, Presagia Inc, during the conduct of the study; FJ reports grants and research funding from Novartis, Genentech, BioMed Valley Discoveries, Plexxikon, Piqur, Symphogen, Bayer, and Fujifilm Corporation, Astex, Asana, Astellas, Agios, Proximagen, Bristol-Myers Sqibb, and Upsher-Smith Laboratories, research funding & SAB from Deciphera, SAB from IFM Therapeutics, Synlogic, Gaurdant Health, Ideaya, and PureTech Health, and services as paid consultant & ownership interests in Trovagene, and paid consultant in Immunomet, Sotio, and Jazz Pharmaceuticals, outside the submitted work; FM-B reports grants from Aileron, AstraZeneca, Bayer Healthcare Pharmaceutical, Calithera Biosciences Inc., Curis Inc., CytomX Therapeutics Inc., Daiichi Sankyo Co. Ltd., Guardant Health Inc., Millennium Pharmaceuticals, Novartis, Taiho Pharmaceutical Co.; personal fees for advisory from Seattle Genetics Inc., Immunomedics, Inflection Biosciences, Mersana Therapeutics, Silverback Therapeutics, Spectrum Pharmaceuticals, Zentalis; personal fees from Aduro, BioTech Inc, Alkermes, F. Hoffman-La Roche Ltd, IBM Watson, Jackson Laboratory, Kolon Life Science, OrigiMed, PACT Pharma, Parexel International, Pfizer Inc., Samsung Bioepis, Tyra Biosciences, Xencor, Zymeworks; personal fees for travel related from Beth Israel Deaconess Medical Center, grants and personal fees for Consulting from Genentech, Debio, and eFFECTOR Therapeutics; personal fees for consulting and advisory committee from Seattle Genetics Inc., personal fees for advisory and grants Puma Biotechnology Inc.; grants from Chugai Biopharmaceuticals, Mayo Clinic, and Rutgers Cancer Institute of New Jersey outside the submitted work; RJ reports personal fees from Kaleido Biosciences, Seres Therapeutics, Merck, Prolacta Bioscience, MaaT Pharma, MicroBiomeDX, Karius, Ziopharm Oncology, and holds a patent with Seres Therapeutics, outside the submitted work; AN reports research support and non-financial support from Merck Sharp & Dohme Corp., grants from NCI/NIH, research support from The University of Texas MD Anderson Cancer Center, during the conduct of the study; grants from NCI, research support from EMD Serono, MedImmune, Healios Onc. Nutrition, Atterocor, Amplimmune, ARMO BioSciences, Karyopharm Therapeutics, Incyte, Novartis, Regeneron, Merck, Bristol Myers Squibb, Pfizer, CytomX Therapeutics, Neon Therapeutics, Calithera BioSciences, TopAlliance BioSciences, Eli Lilly, Kymab, Arcus, and PsiOxus, A non-financial support for travel and accommodation from ARMO BioSciences, and has served as an advisory board member for Novartis, Kymab, Genome & Company, and CytomX Therapeutics outside the submitted work. TM, LZ, DDK, AB, JG, AZ, CP declare no competing interests.